Apheresis Market Size, Share, Growth, and Industry Analysis, By Type (Devices,Disposables), By Application (Renal Disorders,Hematological Disorders,Neurological Disorders,Autoimmune Disorders,Other Applications), Regional Insights and Forecast to 2035

Apheresis Market Overview

The global Apheresis Market in terms of revenue was estimated to be worth USD 1990.83 Million in 2026 and is poised to reach USD 3762.75 Million by 2035, growing at a CAGR of 7.33% from 2026 to 2035.

The global Apheresis Market involves an estimated 3 billion blood separation procedures annually, with approximately 75 percent performed in hospitals and blood banks. In 2023 North America accounted for about 36 percent share of global procedures. Disposable kits comprised around 65 percent of usage volume in 2023, while devices constituted the other 35 percent. Plasmapheresis represented roughly 43 percent of total apheresis procedures, with plateletpheresis around 25 percent and leukapheresis near 20 percent. Annual therapeutic apheresis procedures in the U.S. exceeded 1 million in 2023.

In the USA in 2023 the apheresis equipment segment reached approximately 918 million units in market size terms, with a 71.9 percent share held by disposable apheresis kits. Blood component collections grew by 1.7 percent between 2019 and 2021. About 807,000 Americans figure with kidney failure, some requiring regular apheresis; 37 million Americans have kidney disease. New cancer cases numbered about 1,958,310 in 2023, with around 609,820 associated deaths. Approximately 1 million therapeutic apheresis treatments occurred in the U.S. in 2023. Demand in community hospitals and clinics continues rising.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: 65 percent of global apheresis demand linked to plasma‑derived product collection
• Major Market Restraint: 40 percent of smaller clinics cite high capital barriers to adopting apheresis devices
• Emerging Trends: 55 percent of new investments focused on integrated EHR‑enabled automated systems
• Regional Leadership: North America held 36 percent share of procedures in 2023
• Competitive Landscape: Top five companies collectively account for 55 percent of market share
• Market Segmentation: Devices captured 35 percent of usage volume; disposables 65 percent
• Recent Development: 50 percent of recent R&D investments targeted centrifugation device enhancements

Apheresis Market Trends

The apheresis market is witnessing significant transformation driven by technological advancements, increasing therapeutic applications, and demand for safer, more efficient procedures. In 2023, automated apheresis systems made up nearly 55% of newly installed devices globally, highlighting a shift toward real-time monitoring and EHR integration. Single-use disposables accounted for approximately 65% of global usage, reflecting rising infection control awareness and regulatory compliance requirements. Plasmapheresis remained the dominant procedure type, comprising about 43% of total apheresis sessions, largely due to growing demand for plasma-derived therapies in autoimmune and neurological conditions.

Rising incidence of chronic illnesses has fueled procedure growth over 1 million therapeutic apheresis procedures were performed in the U.S. alone in 2023. Furthermore, disposables with DEHP-free and biodegradable materials are emerging, accounting for about 10% of new kit launches globally. Personalized and precision medicine applications now contribute to nearly 20% of R&D pipelines in the apheresis industry, particularly in oncology and neurology.

Apheresis Market Dynamics

DRIVER

"Rising demand for plasma‑derived products"

In 2023 global plasma protein therapeutics market reached about 24 billion USD‑equivalent and drove approximately 65 percent of apheresis demand. Hospitals and blood banks processed roughly 75 percent of total procedures volume. Around 1 million therapeutic apheresis procedures occurred in the U.S. in 2023. Centrifugation devices accounted for about 60 percent of installed apheresis systems. Disposable kit adoption was 65 percent globally, improving infection safety and single‑use compliance across 40 percent of procedures in developing regions.

RESTRAINT

"High capital investment requirements"

Approximately 40 percent of smaller health facilities report that advanced apheresis device acquisition is cost prohibitive. Training requirements affect about 35 percent of practitioners, limiting uptake in rural areas. Capital barriers delay replacement cycles that would otherwise enable adoption of newer centrifugation models in around 45 percent of medium clinics. Roughly 30 percent of facilities cite lack of trained apheresis specialists as a reason for under‑utilized capacity.

OPPORTUNITY

"Technological innovations in automation and disposables"

Emerging automated platforms represent approximately 55 percent of recent device investments. Apheresis kit disposables account for roughly 65 percent of volume, presenting opportunity to innovate with eco‑friendly materials. Plasmapheresis operations at 43 percent of procedure mix demonstrate a large target segment. Personalized medicine apheresis spinoffs comprise around 20 percent of R&D pipelines, especially for autoimmune indications.

CHALLENGE

"Supply chain and regulatory complexity"

About 35 percent of global suppliers report supply chain issues disrupting component deliveries in 2023. Price competition among manufacturers contributes to margin compression across 55 percent of product lines. Regulatory approvals delay product rollouts in roughly 30 percent of cases. Ethical and DEHP plastic exposure concerns affect 18 percent of plateletpheresis disposables usage, requiring innovation in materials.

Apheresis Market Segmentation

Global apheresis market divides by type and application. Devices comprised roughly 35 percent of installed systems and disposables 65 percent of usage volume. Applications include renal disorders (35 percent), hematological disorders (30 percent), neurological disorders (15 percent), autoimmune disorders (10 percent), other applications (10 percent).

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Devices: Centrifugation devices accounted for nearly 60 percent of device installations in 2023, favored in therapeutic plasmapheresis and leukapheresis. Membrane separation devices made up about 40 percent of installations. Centrifugation systems enable high throughput: each unit handles up to 5 liters per session in under 120 minutes. Devices usage in hospitals reached approximately 75 percent share of installed units, while clinics and community centers accounted for about 25 percent.

The global apheresis devices segment is projected at USD 820 million in 2025 with approximately 44 percent market share and CAGR of 7.33 percent.

Top 5 Major Dominant Countries in the Devices Segment

• United States: estimated devices market size USD 280 million in 2025, 34 percent share, CAGR 7.33 percent.
• Germany: devices market around USD 85 million in 2025, 10 percent share, CAGR 7.33 percent.
• Japan: devices segment nearing USD 78 million in 2025, 9.5 percent share, CAGR 7.33 percent.
• China: devices size close to USD 74 million in 2025, 9 percent share, CAGR 7.33 percent.
• United Kingdom: devices estimated USD 66 million in 2025, 8 percent share, CAGR 7.33 percent.

Disposables: apheresis kits accounted for about 65 percent of global usage volume in 2023. Single‑use blood bag sets, filters, tubing and consumables represent major constittuent: bag sets 40 percent, filters 25 percent, accessories 35 percent of disposables. Usage in North America was 40 percent volume share, Europe 20 percent, Asia‑Pacific 30 percent, Middle East/Africa 10 percent. Hospitals used 80 percent of disposables, clinics 20 percent.

The global apheresis disposables segment is expected at USD 1 034 million in 2025, holding about 56 percent market share and CAGR 7.33 percent.

Top 5 Major Dominant Countries in the Disposables Segment

• United States: disposables market size USD 320 million in 2025, 31 percent share, CAGR 7.33 percent.
• Germany: approx USD 110 million in disposables in 2025, 11 percent share, CAGR 7.33 percent.
• Japan: disposables around USD 95 million in 2025, 9.2 percent share, CAGR 7.33 percent.
• China: about USD 92 million in disposables in 2025, 8.9 percent share, CAGR 7.33 percent.
• United Kingdom: roughly USD 78 million in disposables in 2025, 7.5 percent share, CAGR 7.33 percent.

BY APPLICATION

Renal Disorders: applications, including treatments for renal failure and nephrotic syndrome, comprised around 35 percent of all therapeutic apheresis procedures in 2023. In the U.S., some 807,000 individuals with kidney failure rely on apheresis interventions periodically. Hospitals handled approximately 90 percent of renal apheresis cases, with clinics covering 10 percent.

Renal disorders application in apheresis is valued at USD 650 million in 2025, with 35 percent share and CAGR 7.33 percent.

Top 5 Major Dominant Countries in Renal Disorders Application

• United States: renal segment size USD 230 million in 2025, 35 percent share, CAGR 7.33 percent.
• Germany: renal apheresis around USD 70 million in 2025, 10.8 percent share, CAGR 7.33 percent.
• Japan: USD 65 million in renal application in 2025, 9.8 percent share, CAGR 7.33 percent.
• China: renal procedures USD 64 million in 2025, 9.6 percent share, CAGR 7.33 percent.
• United Kingdom: renal apheresis USD 60 million in 2025, 9.2 percent share, CAGR 7.33 percent.

Hematological Disorders: treatments (e.g. thrombocytopenia, sickle cell, leukemia) made up roughly 30 percent of global apheresis procedures. Estimated 100,000 Americans live with sickle cell disease requiring repeat transfusion or apheresis. Plateletpheresis represented about 25 percent of total procedures, leukapheresis around 20 percent.

Hematological disorders application estimated at USD 550 million in 2025, representing 30 percent share, CAGR 7.33 percent.

Top 5 Major Dominant Countries in Hematological Disorders Application

• United States: hematological share USD 165 million in 2025, 30 percent, CAGR 7.33 percent.
• Germany: around USD 60 million in hematological disorders, 10.9 percent share, CAGR 7.33 percent.
• Japan: hematological apheresis approx USD 55 million in 2025, 10 percent share, CAGR 7.33 percent.
• China: hematological usage USD 54 million in 2025, 9.8 percent share, CAGR 7.33 percent.
• United Kingdom: about USD 50 million in hematological application in 2025, 9.1 percent share, CAGR 7.33 percent.

Neurological Disorders: such as Guillain‑Barré and myasthenia gravis accounted for around 15 percent of apheresis application mix in 2023. Plasmapheresis use in neurology comprised about 43 percent of total plasmapheresis procedures, with hospitals delivering nearly 95 percent of such treatments.

Neurological disorders application projected at USD 260 million in 2025, with 14 percent share, CAGR 7.33 percent.

Top 5 Major Dominant Countries in Neurological Disorders Application

• United States: neurological apheresis USD 90 million in 2025, 14 percent share, CAGR 7.33 percent.
• Germany: neurological usage USD 28 million in 2025, 4.8 percent share, CAGR 7.33 percent.
• Japan: neurological application around USD 27 million in 2025, 4.6 percent share, CAGR 7.33 percent.
• China: neurological segment USD 26 million in 2025, 4.5 percent share, CAGR 7.33 percent.
• United Kingdom: neurological disorders about USD 24 million in 2025, 3.9 percent share, CAGR 7.33 percent.

Autoimmune Disorders: interventions represented approximately 10 percent of apheresis volume. Patients with conditions like myasthenia gravis and lupus engaged in plasmapheresis usage. Emerging immunoadsorption procedures formed around 5 percent of autoimmune‑related apheresis treatments.

Autoimmune disorders application estimated at USD 185 million in 2025, 10 percent market share, CAGR 7.33 percent.

Top 5 Major Dominant Countries in Autoimmune Disorders Application

• United States: autoimmune application USD 65 million in 2025, 10 percent share, CAGR 7.33 percent.
• Germany: autoimmune therapies USD 20 million in 2025, 3.4 percent share, CAGR 7.33 percent.
• Japan: autoimmune treatment USD 19 million in 2025, 3.3 percent share, CAGR 7.33 percent.
• China: autoimmune usage around USD 18 million in 2025, 3.2 percent share, CAGR 7.33 percent.
• United Kingdom: autoimmune disorders USD 17 million in 2025, 2.9 percent share, CAGR 7.33 percent.

Other Applications: therapeutic uses including lipidpheresis, photopheresis, stem cell collection represented about 10 percent of total apheresis procedures in 2023. Stem cell collection accounted for around 6 percent of procedures, lipidpheresis near 4 percent.

Other applications such as photopheresis, lipidpheresis and stem cell collection estimated at USD 210 million in 2025, 11 percent share, CAGR 7.33 percent.

Top 5 Major Dominant Countries in Other Applications

• United States: other application segment USD 75 million in 2025, 11 percent share, CAGR 7.33 percent.
• Germany: other uses around USD 25 million in 2025, 3.7 percent share, CAGR 7.33 percent.
• Japan: other application USD 23 million in 2025, 3.4 percent share, CAGR 7.33 percent.
• China: other uses USD 22 million in 2025, 3.3 percent share, CAGR 7.33 percent.
• United Kingdom: other applications USD 21 million in 2025, 3.1 percent share, CAGR 7.33 percent.

Apheresis Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

Procedures share 36 percent globally in 2023 U.S. equipment usage at 918 million units equivalent term Disposable kits share 71.9 percent of U.S. usage Blood bank/hospital end‑users 75 percent Renal disease applications 35 percent of procedures.

North America apheresis market is projected at USD 670 million in 2025, with approximately 36 percent regional share and CAGR 7.33 percent.

North America – Major Dominant Countries in the Apheresis Market

• United States: market size USD 610 million in 2025, 91 percent regional share, CAGR 7.33 percent.
• Canada: around USD 20 million in 2025, 3 percent share, CAGR 7.33 percent.
• Mexico: approx USD 15 million in 2025, 2.2 percent share, CAGR 7.33 percent.
• Cuba: estimated USD 13 million in 2025, 1.9 percent share, CAGR 7.33 percent.
• Puerto Rico: about USD 12 million in 2025, 1.8 percent share, CAGR 7.33 percent.

EUROPE

region held roughly 20 percent of disposable kit volume and 25 percent of plasmapheresis procedure volume in 2023. Hospitals accounted for around 70 percent of usage in Europe. Centrifugation devices represented about 55 percent installations. Hematological applications comprised 30 percent of European procedures; neurological 15 percent; autoimmune 10 percent. Disposables volume share in 2023 about 20 percent, devices 80 percent installations.

Europe’s apheresis market anticipated at USD 460 million in 2025, with around 25 percent geographic share and CAGR 7.33 percent.

Europe – Major Dominant Countries in the Apheresis Market

• Germany: Europe devices and disposables combined USD 110 million in 2025, 24 percent share, CAGR 7.33 percent.
• United Kingdom: USD 70 million in 2025, 15 percent share, CAGR 7.33 percent.
• France: about USD 60 million in 2025, 13 percent share, CAGR 7.33 percent.
• Italy: approx USD 50 million in 2025, 11 percent share, CAGR 7.33 percent.
• Spain: around USD 45 million in 2025, 10 percent share, CAGR 7.33 percent.

ASIA-PACIFIC

accounted for 30 percent share of disposable kit volume in 2023 and about 28 percent of procedures globally. Hospitals provided 65 percent of services, clinics 35 percent. Plasmapheresis comprised 40 percent of procedure mix. Centrifugation devices 50 percent of installed base, membrane separation 50 percent. Renal and hematological applications combined 60 percent; neurological 12 percent; autoimmune 8 percent.

Asia apheresis market size is forecast at USD 560 million in 2025, representing 30 percent share and CAGR 7.33 percent.

Asia – Major Dominant Countries in the Apheresis Market

• Japan: market size USD 120 million in 2025, 21 percent share, CAGR 7.33 percent.
• China: USD 115 million in 2025, 20.5 percent share, CAGR 7.33 percent.
• India: about USD 90 million in 2025, 16 percent share, CAGR 7.33 percent.
• South Korea: estimated USD 80 million in 2025, 14 percent share, CAGR 7.33 percent.
• Australia: around USD 70 million in 2025, 12.5 percent share, CAGR 7.33 percent.

MIDDLE EAST & AFRICA

region represented about 10 percent of global disposable kit volume in 2023 and 8 percent of procedure count. Hospitals handled 60 percent share, clinics 40 percent. Plasmapheresis made up 35 percent of procedures; hematological 25 percent; renal 20 percent; neurological & autoimmune collectively 20 percent. Devices installations: centrifugation 45 percent, membrane 55 percent.

Middle East and Africa apheresis market projected at USD 120 million in 2025, with 8 percent regional share and CAGR 7.33 percent.

Middle East and Africa – Major Dominant Countries in the Apheresis Market

• Saudi Arabia: market size USD 30 million in 2025, 25 percent regional share, CAGR 7.33 percent.
• South Africa: approx USD 25 million in 2025, 21 percent share, CAGR 7.33 percent.
• United Arab Emirates: USD 20 million in 2025, 17 percent share, CAGR 7.33 percent.
• Egypt: about USD 18 million in 2025, 15 percent share, CAGR 7.33 percent.
• Nigeria: estimated USD 15 million in 2025, 12.5 percent share, CAGR 7.33 percent.

List of Top Apheresis Companies

• KANEKA CORPORATION
• Braun Melsungen AG
• TERUMO BCT
• Otsuka Holdings Co. Ltd.
• HemaCare
• TORAY INDUSTRIES INC
• Bioelettronica Srl
• Fresenius Kabi AG
• KAWASUMI LABORATORIES INC.
• Asahi Kasei Medical Co. Ltd.
• Haemonetics Corporation
• Isto Biologics (Arteriocyte Medical Systems Inc).
• Kidde-Fenwal Inc.
• Cerus Corporation
• Mallinckrodt
• Shiga University of Medical Science

Asahi Kasei Medical Co. Ltd.: holds approximately 15 percent of global apheresis market share in 2023

1. Braun Melsungen AG: holds approximately 12 percent of global apheresis market share in 2023

Investment Analysis and Opportunities

The apheresis market has attracted substantial investments across device innovation, disposable development, and regional expansion. In 2023, approximately 55% of global capital expenditures were directed toward automated apheresis systems, featuring enhanced data integration, shorter procedure times, and user-friendly interfaces. Around 30% of investments originated from Asia-Pacific and Latin America, where rising healthcare infrastructure and increased prevalence of chronic disorders are driving demand for therapeutic apheresis. Single-use disposables accounted for nearly 65% of market volume, presenting lucrative opportunities for innovation in biocompatible, DEHP-free, and eco-friendly materials. Investment in such advanced disposables rose by 15% year-over-year in 2023, particularly in the European and North American markets.

Stem cell apheresis and immunoadsorption are gaining traction, attracting around 20% of new R&D funding due to increasing application in oncology and autoimmune conditions. The growing need for outpatient and point-of-care apheresis units has opened further investment channels, with mobile systems comprising 10% of new installations globally in 2023. Additionally, public-private partnerships are on the rise, especially in countries aiming to improve national blood transfusion and plasma collection programs. These investment trends signal robust growth potential and open strategic entry points for manufacturers, distributors, and healthcare investors targeting the global apheresis market.

New Product Development

The apheresis market has seen accelerated innovation between 2023 and 2025, with new product development focused on automation, efficiency, and patient safety. Approximately 60% of new devices introduced during this period were automated systems capable of reducing treatment time by up to 25%, offering real-time monitoring and seamless electronic health record (EHR) integration. These advancements have significantly improved workflow in hospitals and blood centers, particularly in North America and Europe. Disposable kits have also undergone substantial innovation, with nearly 18% of new kits launched in 2023 designed using DEHP-free and biocompatible materials to meet growing safety and regulatory demands.

In addition, eco-friendly packaging and biodegradable components accounted for 10% of product development efforts, especially in environmentally regulated markets like the EU and Japan. The expansion of personalized treatment protocols has led to the development of specialty apheresis kits tailored for autoimmune and neurological disorders. About 20% of recent device and consumable innovations targeted immunoadsorption and photopheresis procedures. Manufacturers are also investing in miniaturized, portable apheresis machines, with 15% of new devices suitable for use in outpatient or mobile care settings.

Five Recent Developments

• Asahi Kasei launched a new centrifugation system in 2024 reducing procedure time by 25 percent.
• Braun introduced DEHP‑free disposable kits in 2023 capturing approximately 18 percent of European kit market that year.
• Haemonetics rolled out EHR‑integrated automation in 2025 representing 55 percent of its recent device portfolio.
• Terumo BCT unveiled portable point‑of‑care apheresis unit in 2024 representing 20 percent of its new device shipments.
• Cerus Corporation developed photopheresis disposable accessories in 2023 which accounted for 6 percent of new application lines.

Report Coverage of Apheresis Market

The Apheresis Market Report delivers an in-depth analysis of key market segments, trends, drivers, and competitive dynamics shaping the global landscape. The report covers two primary product types devices and disposables with disposables accounting for approximately 65% of global usage volume and devices representing about 35% of installations. It provides detailed segmentation by application, including renal disorders (35% share), hematological disorders (30%), neurological disorders (15%), autoimmune disorders (10%), and other applications (10%) such as lipidpheresis and stem cell collection.

Geographically, the report outlines performance across major regions: North America led with 36% of global procedures in 2023, followed by Asia-Pacific (30%), Europe (25%), and the Middle East & Africa (8%). The report highlights end-user analysis, with hospitals and blood banks making up roughly 75% of total procedure volumes, while clinics and outpatient centers comprise the remaining 25%. The competitive landscape section evaluates leading market participants, who collectively control about 55% of global share. It also includes key technological innovations such as automation, EHR integration, and eco-friendly disposables.

Apheresis Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1990.83 Million in 2026
Market Size Value By	USD 3762.75 Million by 2035
Growth Rate	CAGR of 7.33% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Devices Disposables By Application : Renal Disorders Hematological Disorders Neurological Disorders Autoimmune Disorders Other Applications
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample